Ireland-based ICON has launched a new patient engagement platform to support people interested in participating in clinical trials by offering study specific information.

The platform also provides patients with connectivity to the nearest trial site. In addition, it improves visibility of potential trial subjects for sponsors and sites.

Outreach programmes for patient enrolment will be developed by combining standard approaches with digital channels and patient advocacy collaborations. These programmes are intended to attract patients to a study branded website that will be hosted on the platform.

The platform comes with a user-friendly interface to guide patients to new and ongoing trials in their particular indication. It features a pre-qualification questionnaire to help determine the suitability of the study.

ICON Site & Patient Solutions senior vice-president EB McLindon said: “Access to patients continues to be the biggest challenge for sponsors, impacting speed to market and overall drug development costs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We have used our understanding of patients gained through managing thousands of trials to develop this patient engagement platform and ease the burden on sites and patients. This will increase the predictability and speed of patient recruitment.”

The company added that the new platform enables at-home discussion of the possibility of trial participation as a clinical care option at home.

When a patient decides to register interest, the platform provides an option to select their nearest investigative site. This in turn enhances access to potential patients for sponsors.

Furthermore, site staff will be able to view the number of completed pre-qualification questionnaires for monitoring and reporting on progress to sponsors.